1,084
Participants
Start Date
May 1, 2019
Primary Completion Date
January 1, 2027
Study Completion Date
April 1, 2027
Piperacillin/tazobactam
4.5 grams QID
Meropenem
1 gram TID
RECRUITING
Sanz Medical Center-Laniado Hospital, Netanya
RECRUITING
Rambam Health Care Campus, Haifa
RECRUITING
University of Calgary, Cumming School of Medicine, O'Brien Institute for Public Health, Calgary
RECRUITING
Surrey Memorial Hospital - Fraser Health Authority, Surrey
RECRUITING
Eastern Health, St. John's
RECRUITING
Kingston General Hospital, Kingston
RECRUITING
McGill University Health Centre, Montreal, Quebec
RECRUITING
Soroka Medical Center, Beersheba
RECRUITING
Hadassah Medical Center, Jerusalem
RECRUITING
Meir Medical Center, Kfar Saba
RECRUITING
Rabin Medical Center, Beilinson Campus, Petah Tikva
RECRUITING
Sheba Medical Center (Tel HaShomer), Tel Aviv
RECRUITING
Sourasky Medical Center, Tel Aviv
RECRUITING
Jewish Genral Hospital, Montreal
Collaborators (1)
Rabin Medical Center
OTHER
University of Modena and Reggio Emilia
OTHER
Tel Aviv Medical Center
OTHER
Meir Medical Center
OTHER
Soroka University Medical Center
OTHER
The Chaim Sheba Medical Center
OTHER
McGill University Health Centre/Research Institute of the McGill University Health Centre
OTHER
Jewish General Hospital
OTHER
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Hadassah Medical Organization
OTHER
Rambam Health Care Campus
OTHER